
GenSight Biologics Investor Relations Material
Latest events

Q1 2025 TU
7 Apr, 2025

H2 2024
19 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from GenSight Biologics SA
Access all reports
GenSight Biologics SA is a French biotechnology company focused on developing gene therapies for neurodegenerative diseases affecting vision. The company's primary area of research involves treatments for inherited retinal diseases, including Leber Hereditary Optic Neuropathy (LHON), a condition that leads to sudden vision loss. GenSight Biologics uses proprietary gene therapy platforms to target and potentially restore function in damaged retinal cells. Its therapies are designed to offer long-lasting effects with a single administration. The company is headquartered in Paris, France, and its shares are listed on Euronext Paris.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
SIGHT
Country
🇫🇷 France